Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2Recruiting 1Completed 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Non-Muscle Invasive Bladder Neoplasms 2Urologic Neoplasms 1Urinary Bladder Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma in Situ 1

Interventions

Gemcitabine 4BCG Vaccine 4Mitomycin 3ALT-803 3durvalumab 2dodecyl maltoside 2Docetaxel 2erdafitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Non-Muscle Invasive Bladder Neoplasms × dodecyl maltoside × Clear all
NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

CG Oncology, Inc.

Phase 3 Active not recruiting
367 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡